Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro

Drug Metabolism and Disposition

Volumn 28, Issue 8, 2000, Pages 895-898

  Wandel, C ^a   Kim, R B ^a   Guengerich, F P ^a   Wood, A J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; GLYCOPROTEIN P; MIBEFRADIL;

ANIMAL CELL; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MIBEFRADIL; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0033863264     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L- type calcium channel antagonist
2. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: Favorable hemodynamics and pharmacokinetics
3. The mdr1 gene-product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin
4. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
5. Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines
6. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
7. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist
8. Serious interaction between mibefradil and tacrolimus
9. Incidence of adverse drug reactions in hospitalized patients: A meta- analysis of prospective studies
10. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr la P- glycoprotein
11. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
12. The carbon monoxide-binding pigment of liver microsomes
13. Multidrug resistance
14. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
15. Disruption of the mouse mdr1a P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drug
16. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
17. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclospotin A
18. The interaction of the calcium antagonist RO 40-5967 with digoxin, and cyclosporin
19. Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients
20. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier
21. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein
22. In vitro and in vivo drug interactions involving human CYP3A
23. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein-implications for drug-delivery and activity in cancer-chemotherapy
24. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies